LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis
LegalView recently posted detailed information on its Cimzia
information portal regarding the potentially serious side effects caused by the drug and its family known as TNF inhibitors. Among the drug's potential side effects are the development of fatal infections and cancer-causing agents for y...
Does the Crowded TNF Market Really Need Two New Agents? Rheumatologists Provide Insight in the Wave One Report of LaunchTrends(TM): SIMPONI and CIMZIA
EXTON, Pa., July 31 /PRNewswire/ -- BioTrends Research Group, Inc. announces the release of the wave one LaunchTrends (TM): SIMPONI and CIMZIA
report. The survey was completed by U.S. Rheumatologists in late June 2009.
While awareness of both new TNF antagonists is relatively h...
U.S. Payers Intend to Limit Preferred Coverage to Only One Immune Biologic
... help some brands remain competitive with Remicade and Humira," said Michael Malecki, Ph.D., product manager for Formulary Forum. "For instance, UCB's cimzia
received U.S. approval for rheumatoid arthritis in May, so with this additional indication, UCB now has greater flexibility in being able to use tende...
Certain Arthritis, Crohn's Drugs May Raise Kids' Cancer Risk: FDA
...hat causes inflammation and damage to bones, cartilage and other tissue. They include Remicade (infliximab), Enbrel (etanercept), Humira (adalimumab), cimzia
(certolizumab pegol) and Simponi (golimumab).
"FDA announced that it has completed its analysis of TNF blockers and has concluded that there is an...
Intravenous Immune Biologics Will Suffer from the Pending Shift in Coverage from the Medical to the Pharmacy Benefit
...s say coverage of immune biologics will shift from a medical benefit to a pharmacy benefit by 2014, citing Centocor Ortho Biotech's Remicade and UCB's cimzia
among products that will be most affected by this shift. According to the new Formulary Forum report entitled Formulary Advantages in Immune Biologic...
Once Monthly Dosing: How Much of a Competitive Advantage is it? Rheumatologists Provide Insight in the Baseline Report of LaunchTrends(TM): SIMPONI(TM)
... TNF agent into the mix. In addition to the recent launches of SIMPONI and cimzia
there is significant interest among Rheumatologists in Roche's ACTEMRA(R) (...th post launch, will be fielded on June 22 and will be expanded to include cimzia
in the competitive set. The results will be published in mid-July.
Cimzia(R) (certolizumab pegol) Now Available for Self-Administration in Adult Patients With Moderate to Severe Crohn's Disease
...minister their therapy every four weeks."
(R) prefilled syringe, designed by UCB in partner...D GRIPS (R) is available exclusively for use with cimzia
(R) . The companies recognized the importance of d... opening and resealing.
In addition, the new cimzia
(R) prefilled syringe carries the Arthritis Found...
UCB's CIMZIA(R) (certolizumab pegol) Approved by the U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
Notes to the editor:
(R) is the only PEGylated anti-TNF (Tumor Necrosis Factor). cimzia
(R) has a high affinity for human TNF-alpha, se...
BioTrends Prepares to Field ChartTrends(TM) Reports to Cover the Use of Biologic Agents in Psoriasis and Rheumatoid Arthritis
...ionally, the study will assess familiarity and interest in several late stage biologics in development (Roche's ACTEMRA, Centocor's SIMPONI, and UCB's cimzia
in RA and Centocor's STELARA and Abbott's ABT-874 in Psoriasis). BioTrends, which has been offering ChartTrends(TM) reports since 2005, plans to ...
Eighty-Nine Percent of Surveyed Rheumatologists Say They Will Prescribe Roche/Chugai's Actemra for Rheumatoid Arthritis
continue, and possibly expand, over the next two years," said Cindy Mundy,
Ph.D., director at Decision Resources. "The upcoming launches of cimzia
golimumab will increase the number of TNF-alpha inhibitors approved for
rheumatoid arthritis from three to five. Following the launches of Cimzia
Cimzia in Medical Technology
UCB Presents Long-Term CImzia Data in Crohn's Disease Cimzia
Maintained Long-term Response at Stable Doses, According to
New Data Presented at Digestive Disease Week (DDW)
ATLANTA, May 22, 2007 /PRNewswire/ -- UCB announced today that
new data presented at Digestive Disease Week 2007 (DDW)
demonstrated long-term response and remission in Crohn's dise...
Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)
... to easily remove the syringe.
(R) safety information
Reported serious adve...nuations due to adverse events (5%).
(R) is the only PEGylated anti-TNF (Tumour Necr...
CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
at Week 52). Results also showed that cimzia
together with methotrexate
(MTX) provided ACR 20 r...analysis investigating the rapidity of response to cimzia
monotherapy (FAST 4WARD) and together with MT...The analysis
presented showed that the response to cimzia
treatment was rapid in both
studies with more than...
CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients
...mated comparison of treatment costs and
found that cimzia
offers a cost savings versus other commonly-used
b...howed that 39 percent of
patients who responded to cimzia
treatment after failing infliximab therapy
achieve...howed that 39 percent of
patients who responded to cimzia
treatment after failing infliximab therapy
CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients
... reduction of 5 or more points in CDEIS
scores) to cimzia
treatment. Significant improvements also were show...alysis.
"These data underscore the importance of cimzia
as a comprehensive
treatment option for people fighting Crohn's disease," said Dr. Colombel.
is approved for reducing the signs and symptoms of...
NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting
... other drugs.
Nektar PEGylation technology is also used in eight additional approved
partnered products in the U.S. or Europe today, including UCB's cimzia
Crohn's disease, Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R)
Nektar Therapeutics is a biopharmace...
Current and Emerging Drugs Have No Advantage Over Enbrel in Inhibiting/Slowing the Progression of Rheumatoid Arthritis
...rging therapies that include
ocrelizumab and UCB's cimzia
are also comparable to that of Enbrel.
However, th...lable clinical data for golimumab, ocrelizumab
is not as robust or extensive as those available f...
"While emerging therapies such as golimumab and cimzia
delivery to that of Enbrel due to i...
CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
...ients with active rheumatoid arthritis (RA).
combined with methotrexate was shown to significan...dition, another study demonstrated the efficacy of cimzia
treatment of the signs and symptoms of RA a... Additional new long-term RAPID 1 data showed that cimzia
with methotrexate significantly red...
Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid
...Spain, 14 June 2007 - 7:00 am CET - New pivotal data
(RAPID 1 and RAPID 2) presented at the Annual European Congress of
Rheumatology (EULAR) show that cimzia
(certolizumab pegol), the
first PEGylated, Fc-free anti-TNF, combined with methotrexate
therapy has a rapid and significant effect in reducing the sig...
Cimzia in Biological Technology